Valuation: Ind-Swift Laboratories Limited

Market Cap 11.4B 120M 105M 96.05M 89.58M 170M 173M 1.16B 448M 5.59B 449M 440M 19.26B P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 7.13B 74.91M 65.45M 60.1M 56.05M 106M 108M 724M 280M 3.5B 281M 275M 12.05B EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.56%
Yield 2024 *
-
Yield 2025 -
1 day+2.74%
1 week+6.39%
Current month+1.32%
1 month+25.60%
3 months+49.25%
6 months+127.89%
Current year+133.94%
1 week 197.1
Extreme 197.1
211
1 month 152.8
Extreme 152.8
211
Current year 87.25
Extreme 87.25
211
1 year 87.15
Extreme 87.15
211
3 years 68.72
Extreme 68.72
211
5 years 52.65
Extreme 52.65
211
10 years 15
Extreme 15
211
Manager TitleAgeSince
Chief Executive Officer 74 1995-01-03
Chief Executive Officer 43 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 43 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Date Insider Type Main position Quantity % Market Cap.
24-09-11Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%+6.39%+83.81%+139.51% 183M
+0.26%-0.18%+12.22%+77.92% 47.1B
+8.72%+6.67%+69.77%+119.98% 34.57B
-0.05%+1.26%-3.94%+43.46% 12.38B
-0.85%+0.05%+9.71%+88.63% 11.64B
+0.49%-1.91%+33.16%+121.55% 8.87B
-0.08%+0.92%+21.22%+43.82% 7.1B
+1.44%+2.21%+56.02%-7.83% 6.85B
+1.58%+0.71%+25.18%+224.85% 6.42B
+6.55%+16.01%-27.50%+16.83% 5.61B
Average +2.08%+2.33%+27.97%+86.87% 14.07B
Weighted average by Cap. +2.59%+0.34%+27.74%+87.31%

Financials

2024 2025
Net sales 12.97B 136M 119M 109M 102M 193M 197M 1.32B 510M 6.36B 512M 501M 21.92B 5.62B 59M 51.56M 47.34M 44.15M 83.7M 85.11M 570M 221M 2.76B 222M 217M 9.49B
Net income 4.21B 44.22M 38.64M 35.48M 33.09M 62.73M 63.79M 427M 166M 2.06B 166M 162M 7.11B 2.5B 26.31M 22.99M 21.11M 19.69M 37.32M 37.95M 254M 98.51M 1.23B 98.79M 96.64M 4.23B
Net Debt -4.15B -43.62M -38.12M -35M -32.64M -61.88M -62.93M -421M -163M -2.04B -164M -160M -7.02B -4.27B -44.81M -39.15M -35.95M -33.53M -63.56M -64.63M -433M -168M -2.09B -168M -165M -7.21B
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
26-07-02 206.22 +2.74% 526,610
26-07-01 ₹200.73 -1.38% 701,538
26-06-30 ₹203.53 -0.85% 684,200
26-06-29 ₹205.27 +2.18% 1,889,912
26-06-25 ₹200.90 +3.65% 2,149,139
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock